QI
MACK

QS Investors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

QS Investors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,563
Closed -$15K – 2009
2017
Q2 		$15K Sell
1,563
-23,962
-94% -$489K ﹤0.01% 1585
2017
Q1 		$619K Hold
25,525
– – 0.01% 901
2016
Q4 		$819K Sell
25,525
-9,727
-28% -$415K 0.01% 798
2016
Q3 		$1.76M Hold
35,252
– – 0.01% 672
2016
Q2 		$1.5M Sell
35,252
-7
-0% -$381 0.01% 698
2016
Q1 		$2.32M Buy
35,259
+7
+0% +$365 0.02% 612
2015
Q4 		$2.19M Sell
35,252
-3,193
-8% -$225K 0.02% 642
2015
Q3 		$2.57M Hold
38,445
– – 0.03% 550
2015
Q2 		$3.74M Hold
38,445
– – 0.05% 459
2015
Q1 		$3.59M Buy
+38,445
New +$3.27M 0.04% 462

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QS Investors's MACK Position: Q3 2017 in Review

QS Investors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 1,563 shares — an estimated $15K sold.

QS Investors first reported a position in MACK in Q1 2015 and held it in 10 quarters. The position peaked at $3.74M in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • QS Investors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • QS Investors sold 1,563 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $15K.
  • QS Investors first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
  • QS Investors's Merrimack Pharmaceuticals, Inc. position peaked at $3.74M in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on QS Investors's 13F filing for Q3 2017, filed 14 Nov 2017.